{
    "clinical_study": {
        "@rank": "163238", 
        "arm_group": {
            "arm_group_label": "ISU302", 
            "description": "15~60U/kg (once every 2 weeks for 6 months)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with\n      Type 1 Gaucher disease previously treated with Imiglucerase."
        }, 
        "brief_title": "A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": "Gaucher Disease", 
        "condition_browse": {
            "mesh_term": "Gaucher Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient diagnosed with type-1 Gaucher disease\n\n          -  Patient who was stably treating Gaucher disease with Cerezyme\u00ae and who was\n             maintaining the usage and dosage of Cerezyme\u00ae for at least 6 months prior to study\n             drug administration\n\n          -  Patient aged 2 years or higher\n\n          -  Female patient with contraception during the study period (oral or injectable\n             contraceptive hormones, intrauterine device, physical devices using condom, sponge\n             form, jelly, and femidom, and abstinence)\n\n          -  Patient who signed the informed consent form after hearing the detailed explanation\n             about this study\n\n               -  Definition of the stable treatment of type-1 Gaucher disease:\n\n          -  No neurologic deficit\n\n          -  Normal hemoglobin concentration, and platelet count that has increased to \u2265100,000/\u33a3,\n             or maintained to 100,000/\u33a3\n\n          -  Normal or no deteriorated bone mineral density\n\n          -  Normal or no deteriorated splenomegaly or hepatomegaly\n\n        Exclusion Criteria:\n\n          -  Patient who participated in other clinical studies within 90 days before study drug\n             administration\n\n          -  Patient with unstable hemoglobin and platelet counts for at least 6 months before\n             study drug administration\n\n          -  Patient with hypersensitivity to Cerezyme\u00ae\n\n          -  Patient positive to HIV antibody, hepatitis B antigen, and hepatitis C antibody\n\n          -  Patient with Fe, folic acid, or vitamin B12-deficcient anemia\n\n          -  Patient who received miglustat within 6 months before study drug administration\n\n          -  Patient who received erythrocyte growth factor or chronic systemic corticosteroids\n             within 6 months before study drug administration\n\n          -  Patient who had clinically significant splenic obstruction within 12 months before\n             study drug administration\n\n          -  Pregnant or lactating patient\n\n          -  Patient who had serious concurrent diseases such as infectious diseases or\n             drug-addicted patient\n\n          -  Patient who was considered inappropriate for this study by the investigators or\n             sub-investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "29 Years", 
            "minimum_age": "8 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patient diagnosed with type-1 Gaucher disease"
            }
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053896", 
            "org_study_id": "ISU302-003"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type I Gaucher", 
            "ISU302", 
            "Imiglucerase"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety of ISU302 in patients with Type 1 Gaucher disease previously treated with Cerezyme\u00ae after administering ISU302 alternative to Cerezyme\u00ae", 
            "measure": "Number of participants with Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "From Screening to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053896"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of blood glucocerebrosidase activity for pharmacokinetic assessment after initial study drug administration", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }, 
            {
                "description": "Change in hemoglobin concentration", 
                "measure": "hemoglobin concentration", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }, 
            {
                "description": "Change in platelet count", 
                "measure": "platelet count", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }, 
            {
                "description": "Changes in liver and spleen volumes and liver function", 
                "measure": "liver and spleen volumes and liver function", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }, 
            {
                "description": "Changes in biomarker levels (Acid Phosphatase, Angiotensin Converting Enzyme, and Chitotriosidase)", 
                "measure": "biomarker levels", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }, 
            {
                "description": "Changes in skeletal status and bone mineral density", 
                "measure": "skeletal status and bone mineral density", 
                "safety_issue": "No", 
                "time_frame": "From Screening to Week 24"
            }
        ], 
        "source": "ISU Abxis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ISU Abxis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}